Citations

Clear

634 citation(s) found for "Hall, A".

Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
Elez, E, Taieb, Julien, Xu, Rui-Hua, Taniguchi, Hiroya, Bekaii-Saab, Tanios S., Tie, Jeanne, Chalabi, Myriam , Chen, Zhiyu, Opneja, Aman, Kochenderfer, Mark D., Hong, Yong Sang , Richards, Donald A., Radecka, B., Clancy, Jill, Tonkovyd, Svitlana, Zhang, Xiaosong, Ng, Kimmie, Eng, Cathy , Élez, Elena , Taı̈eb, Julien , Xu, Rui‐Hua , Taniguchi, Hiroya , Bekaii‐Saab, Tanios , Tie, Jeanne , Chen, Zhiyu , Richards, D., Chen, Yiyi , Clancy, Jill S., Zhang, Xiaosong, Ng, Kimmie

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3675 Get It

TPS3675 Background: Multi-agent chemotherapy regimens (eg, mFOLFOX6) ± anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor regimens are currently the standard of care for patients (pts) with mCRC without targetable mutations. However, the 5-year survival rate remains low at approximately 16% (SEER, 2025). The addition of biological therapies (eg, bevacizumab [bev], an anti-VEGF monoclonal antibody) to immune checkpoint inhibitors (ICIs) has demonstrated a synergistic antitumor effect in solid tumors. However, ICI monotherapy has limited activity in mismatch repair proficient (pMMR)/microsatellite stable (MSS) mCRC. Simultaneous bispecific targeting of programmed death 1 (PD-1) and VEGF in conjunction with cytotoxic chemotherapy has the potential to enhance antitumor activity. PF-08634404 is a fully human immunoglobulin G4 (IgG4) bispecific antibody targeting PD-1 and VEGF. A phase 2 study of PF-08634404 with XELOX or mFOLFOX6 demonstrated promising antitumor activity with a manageable safety profile in first-line (1L) mCRC (Xu X, ESMO 2025; Abstract 796P). Methods: Symbiotic-GI-03 (NCT07222800) is an ongoing, double-blind, randomized, phase 3 study evaluating the efficacy and safety of 1L PF-08634404 + mFOLFOX6 vs bev + mFOLFOX6. Inclusion criteria are age ≥18 y; mCRC with measurable disease per RECIST 1.1; no prior systemic therapy for metastatic disease; ECOG PS 0 or 1; and adequate hematologic, hepatic, and renal function. Pts with BRAF V600E-mutant or mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) CRC, active central nervous system metastases, or clinically significant risk of hemorrhage/fistula will be excluded. Approximately 800 pts will be randomized 1:1 to receive PF-08634404 + mFOLFOX6 or bev + mFOLFOX6 until disease progression, unacceptable toxicity, withdrawal of consent, or death. Randomization will be stratified by region (North America, Europe, or rest of world), RAS status (mutant or wildtype), and presence of liver metastasis (yes or no). The dual primary endpoints are progression-free survival (PFS) by blinded independent central review and overall survival; for each, a stratified log-rank test will be used to compare arms. Hazard ratios with corresponding 2-sided 95% CIs will be estimated using a stratified Cox proportional hazards model, and medians will be estimated using the Kaplan-Meier method with corresponding 2-sided 95% CIs calculated using the log(-log) method. Secondary endpoints include PFS by investigator, objective response rate, duration of response, PFS after next-line therapy, safety/tolerability, pharmacokinetics, immunogenicity, and patient-reported outcomes. Enrollment began in December 2025. Clinical trial information: NCT07222800 .
A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk
Eriksson, Mikael , Czene, K, Scott, C, Stoddard, Shawn, Smith, Hugh, Hall, Per , Vachon, C, Scott, Christopher G. , Vachon, Celine M. , Czene, Kamila , Czene, Kamila , Scott, Christopher , Vachon, Celine M. , Hall, Per N , Eriksson, Mikael , Stoddard, Shawn M.

Mayo Clinic

Science Translational Medicine | May 20, 2026 | Volume: 18 | Issue: 850 | Pages: No page available

10.1126/scitranslmed.ady7414 | PMID 42160452 Get It

Image-derived artificial intelligence (AI) risk models have shown promise in short-term risk assessment for improving breast cancer (BC) screening. No image-derived long-term AI risk model for primary prevention has been developed and externally validated. Individuals aged 31 to 94 years were recruited between 2010 and 2020 in two population-based case cohorts (Olmsted County, Minnesota, US, and KARMA, Sweden) and one hospital-based case-control study (EMBED, Atlanta, US). Median follow-up in the case cohorts was 10 years, with BCs diagnosed through June 2022. Additional validation was performed in EMBED with 3-year follow-up. An AI risk model was developed in Sweden, and we report independent validation in Olmsted/KARMA/EMBED. Absolute 10-year risks were estimated at study entry. Time-dependent discriminatory performance [AUC( t )] and expected-to-observed events (E/O) were estimated. Comparisons were performed with clinical risk tools and the image-based Mirai tool. Across Olmsted/KARMA, 8696 individuals (mean age, 54.4±10.6) and 1633 individuals with incident BC (mean age, 57.0±10.6) were included. Average 10-year risks were 3.83 and 3.14%, and E/O ratios were 0.99 and 0.99. Ten-year AUC( t ) for invasive BCs were 0.72 in Olmsted and 0.72 in KARMA. Similar discriminatory results were observed in EMBED. Our AI risk tool performed significantly better than Mirai in Olmsted/KARMA/EMBED. In KARMA, in the top 10% of high-risk individuals, the AI risk tool predicted 33% of BCs compared with 23%/20%/24% predicted by Tyrer-Cuzick-v8/BCSC-v3/Mirai (all P < 0.01). The 10-year image-derived AI risk model showed significantly higher performance than clinical risk models and Mirai in diverse populations, supporting its clinical potential for primary prevention.
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology,
Rilland, Eddy D. Zandee van , Fayad, Laura M. , Link, Thomas M. , Davis, Kirkland W. , Wu, Jim S. , Chang, Eric Y. , Chow, Lawrence C. , Desai, Shaun C., Fritz, Jan, Gorbachova, Tetyana , Gray, Mingyang L., Gross, Joel A. , Ha, Patrick K., Halle, Tyler R. , Hall, M. Kennedy, Lee, Mark A. , Mann, Edana D. , Obey, Mitchel R. , Osgood, Greg M., Patel, Zara M. , Rendon, Juan M. , Sabbatini, Amber K. , Tannoury, Chadi , Yu, Joseph S. , Boutin, Robert D. , Zandee van Rilland, Eddy D , Brown, Ian P , Chang, Eric Y , Chow, Lawrence C , Gatz, J David , Garner, Hillary W , Gorbachova, Tetyana , Guermazi, Ali , Halle, Tyler R , Hanna, Tarek N , Kornblith, Aaron E , Lopez-Ben, Robert R , Mann, Edana D , Moore, Christopher L. , Obey, Mitchel R , Patel, Zara , Raja, Ali S , Rendon, Juan M , Sabbatini, Amber K , Tannoury, Chadi , Yu, Joseph S , Boutin, Robert D , Link, Thomas M , Desai, Shaun C. , Fritz, Jan , Garner, Hillary W. , Gray, Mingyang Liu , Hall, M. Kennedy , Osgood, Greg Michael

Mayo Clinic

Radiology | May 19, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252309 | PMID 42153836 Get It

Expert consensus recommendations from 21 academic centers were established for appropriate radiography utilization at 12 potentially low-yield anatomic sites through a multidisciplinary process endorsed by six major American medical societies.
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-
Bansal, Ajay, Stoffel, Elena M., Lim, Ramona , Burke, Carol, Hall, Michael J., Singh, Aparajita , Boardman, Lisa A., Samadder, Niloy Jewel, Ballestar, Veroushka, Muller, Charles, Scott, Aaron J. , Xu, Yanfei , Eickhoff, Jens, Meredith, Hyun, Aquila, Lanni , Szabó, Éva , Della’Zanna, Gary , Bengtson, Lisa, Schlom, Jeffrey, Donahue, Renee N., Horn, Lucas A., Palena, Claudia, Gulley, James L., Samaddar, Sohini, Moore, Dennis F., Sharma, Parth, Madan, Rashna , Hurley, Karen, Soon‐Shiong, Patrick , Gabitzsch, Elizabeth, Sender, Lennie, Brenner, Dean, Schuetze, Scott, Djuric, Zora, Barroilhet, L. E., Thompson, Patricia, Bauman, Julie, Khan, Seema, Vilar, Eduardo, Szabo, Eva , Stoffel, Elena M. , Stanich, Peter P. , Patel, Swati , Burke, Carol A. , Hall, Michael J. , Muller, Charles , Benante, Kelly A. , Eickhoff, Jens C. , Zaborek, Jen , Umar, Asad , Richmond, Ellen S. , Schlom, Jeffrey , Donahue, Renee Nicole , Toney, Nicole J. , Palena, Claudia , Gulley, James L , Moore, Dennis F., Djurić, Zora , Barroilhet, Lisa , Vilar, Eduardo

Mayo Clinic

Frontiers in Immunology | May 19, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1809281 | PMID 42238576 Get It

Introduction Lynch syndrome (LS) is a hereditary cancer syndrome that increases risk for colorectal and other cancers. We hypothesize that vaccines against tumor-associated antigens CEA, MUC1, and brachyury, simultaneously delivered in an adenovirus serotype-5 vector (Tri-Ad5) combined with the immune-enhancing IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI) will reduce the incidence of colorectal neoplasms in LS carriers. Methods In this ongoing phase IIB double-blind placebo-controlled trial, two open-label safety phases (SPs) assessed safety of Tri-Ad5 alone (SP1, n=10) and with added NAI (SP2, n=10). A randomized controlled trial (RCT) follows the SPs. After baseline colonoscopy, vaccine dosing occurs at weeks 0, 4 and 8; Tri-Ad5 alone in SP1 and Tri-Ad5 plus NAI in SP2, with identical boosters at Week 52. The RCT phase participants (n=138) were randomized to receive Tri-Ad5 plus NAI or placebo. All participants complete colonoscopy at Weeks 52 and 104 for assessment of the primary endpoint: cumulative colorectal neoplasm incidence. Secondary endpoints include safety, tolerability, and immunogenicity. Results All 20 SP participants (median age 57.5 (range 42–75), 70% female, 15% minority) received all prime and booster series. SP1 participants reported 139 adverse events (AEs) and SP2 participants reported 178. AEs were predominantly grade 1; no treatment-related serious adverse events (SAEs) occurred. The most common treatment-related AEs were reactogenic events including grade 3 rash (without skin necrosis or breakdown) at NAI injection site (100% of SP2 participants). The RCT phase (n=138) recently completed accrual. Discussion In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. Clinical Trial Registration https://clinicaltrials.gov/study/ , identifier NCT05419011.
A complete human pancreatic cancer genome
Wagner, Justin , Keskus, Ayse G. , Oshima, Keisuke K. , Ranallo-Benavidez, T. Rhyker , McDaniel, Jennifer , Šikić, Mile , Lin, Dehui , Paulin, Luis F. , Sedlazeck, Fritz J. , Munding, Elizabeth M., Sanborn, JZ, Carroll, Andrew, Hassaine, Rayan, Cameron, Daniel, Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Zimin, Aleksey V. , Cross, Erin , McGowan, Matthew , Vernich, Michael, Liss, Andrew S., Kocher, Jean-Pierre, Stephens, Zachary, Ahmad, Tanveer, Bryant, Asher , Dwarshuis, Nathan , Thibaud-Nissen, Francoise, Antipov, Dmitry, Koren, Sergey, Phillippy, Adam, Jain, Miten , Wenger, Aaron M. , Eacker, Stephen, Sahraeian, Sayed Mohammad Ebrahim, Boutros, Paul C., Patel, Yash, McConnell, Joseph , Borchers, Matthew , Gerton, Jennifer L. , Kostos, Paxton, Benjamin, Hila, Mootor, Mohammed Faizal Eeman , Xu, Yuan , Asri, Mobin , Miga, Karen H. , Park, Jimin , Paten, Benedict , Choi, Jae Young , Nguyen, L. , Robinson, Dan R. , Vo, Josh N. , Murtaza, Ghulam , Mason, Christopher E. , Cheng, Haoyu, Xiao, Chunlin , English, Adam C , Sedlazeck, Fritz J , Sanborn, J Zachary , Carroll, Andrew , Chang, Pi-Chuan , Cook, Daniel E , Shafin, Kishwar , de Ligt, Joep , Cameron, Daniel , Catreux, Severine , Lee, Yeonghun , Murray, Lisa , Truong, Sean , Brueffer, Christian , Cross, Erin , McGowan, Matthew , Vernich, Michael , Liss, Andrew S , Kocher, Jean-Pierre A , Stephens, Zachary , He, Hua-Jun , He, Zhiyong , Olson, Nathan D , Narzisi, Giuseppe , Jain, Miten , Wenger, Aaron M , Boutros, Paul C , Patel, Yash , Yamaguchi, Takafumi N , McConnell, Joseph , Gerton, Jennifer L , Guarracino, Andrea , Jehangir, Maryam , Mootor, Mohammed Faizal Eeman , Xu, Yuan , Miga, Karen H , Park, Jimin , Paten, Benedict , Luo, Ruibang , Zheng, Zhenxian , Choi, Jae Young , Nguyen, Linh , Vats, Pankaj , Gao, Shenghan , Murtaza, Ghulam , Mason, Christopher E , Barthel, Floris P , Xiao, Chunlin , Logsdon, Glennis A , Kolmogorov, Mikhail , Zook, Justin M , Keskus, Ayse , Ranallo-Benavidez, T Rhyker , Paulin, Luis F. , Sanborn, John Z., Ahmad, Tanveer, Thibaud‐Nissen, Françoise , Antipov, Dmitry , Koren, Sergey , Phillippy, Adam M. , Musunuri, Rajeeva , Eacker, Stephen M. , Yamaguchi, Takafumi N. , Jehangir, Maryam , Benjamin, Hila

Mayo Clinic

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.01.722316 | PMID 42146349 Get It

Summary Cancer genome sequencing is essential for understanding tumor evolution and advancing precision medicine. 1 However, reference gaps and germline variants obscure detection of small and large somatic variants and methylation in repetitive regions. 1–3 It is common for tumor cells to gain or lose chromosome arms due to somatic structural changes that occur inside highly repetitive satellite DNA sequences in the centromeres. 4 To identify the full spectrum of somatic variants, including complex rearrangements, we construct and curate near-complete, haplotype-resolved assemblies of the most recent common ancestor of an early-passage broadly-consented hypodiploid pancreatic cancer cell line and matched normal tissues. The tumor assembly completely recapitulates all 35 tumor chromosomes observed with karyotyping, with multiple translocation-induced hybrid chromosomes. The hybrid chromosomes contain putative functional dicentric and fused centromeres, nested foldback inversions causing 14 breakpoints with a haplotype switch in a single event, and centromeric satellite tandem duplications up to 136 kbp. Direct comparison of tumor and normal assembly haplotypes uncovers >7,000 variants altering >1 Mbp of sequence in repetitive regions that have been hidden by reference gaps and germline variants. 44 % of somatic small variants change representation because they alter germline variants on GRCh38, impacting mutational signatures and kataegis/omikli clusters. Most somatic LINE insertions originate from two hypomethylated non-reference germline LINE insertions, highlighting their impact on insertion mutation burden. These assemblies demonstrate that centromeric, acrocentric, and telomeric regions conventionally excluded from analysis harbor extensive somatic and epigenetic changes. Resolving complete tumor genomes enables a deeper understanding of cancer structural plasticity and the endpoints of breakage-fusion-bridge cycles. These assembled, curated paired normal-tumor benchmarks will serve as a critical foundation for developing future algorithms to characterize the most intractable regions of cancer genomes.
Phase II Trial of Encapsulated Rapamycin to Reduce Polyp Burden Associated with Familial Adenomatous Polyposis
Broderick, Joseph C , Samadder, N. Jewel , Stoffel, Elena , Fang, John C. , Stanich, Peter P. , Wise, Paul , Wright, Randy , Clifton, Travis, Peoples, George E. , Broderick, Joseph , Stoffel, Elena M. , Clifton, Guy T. , Wise, Paul E. , Samadder, N Jewel , Clifton, Guy T , Peoples, George , Burke, Carol A , Broderick, Joseph C, Burke, Carol A.

Mayo Clinic

Clinical Cancer Research | April 28, 2026 | Volume: 32 | Issue: 15 | Pages: 3146-3156

10.1158/1078-0432.ccr-25-4126 | PMID 42048421 Get It

Abstract Purpose: Familial adenomatous polyposis (FAP) confers a significant risk of colorectal/duodenal cancer. Encapsulated rapamycin (eRapa) has demonstrated promise as FAP chemoprevention in early clinical studies. Patients and Methods: Thirty patients with FAP enrolled to three dosing regimens of eRapa (0.5 mg): cohort 1—every other day, cohort 2—daily every other week, or cohort 3—daily. The primary endpoints were safety/tolerability, pharmacokinetics, and percentage change from baseline (PCFB) in colorectal polyp burden (CPB) at 6 months. Secondary endpoints included PCFB total (TPB) and duodenal (DPB) polyp burden and change in International Society for Gastrointestinal Hereditary Tumors stage and Spigelman score at 6 and 12 months. Results: Twenty nine of thirty patients (97%) completed the 12-month study with predictable bioavailability. Low-grade adverse events were frequent but most pronounced in daily dosing. Two patients discontinued treatment related to toxicity. Cohort 1 had the largest decrease median PCFB CPB, DPB, and TPB at 6 months: −39.4 % (IQR, 108.9; P = 0.28), −33.33 % (IQR, 90; P = 0.04), and −38.6 % (IQR, 88.5; P = 0.26), respectively. At 12 months, cohort 2 had the largest decrease median PCFB CPB and TPB: −29.3 % (IQR, 67.6; P = 0.37) and −26.3 % (IQR, 49.5; P = 0.29), respectively. Intermittent dosing cohorts (1 and 2) reduced DPB at 6 months (P = 0.04) and improved TPB at 12 months (P = 0.05) compared with daily dosing. Conclusions: eRapa was safe, tolerable, and showed preliminary efficacy for FAP chemoprevention. The 0.5 mg daily every-other-week schedule will be evaluated in an upcoming phase III trial.
COASY-Associated Disorders as a Differential Diagnosis in Cases with Newborn Screening Results Suggestive of CPT-I
Stander, Zinandré, White, Amy , Lynch, Matthew, Rosati, Justin , Bailey, Diana, Johnson, Jessica, Lee, Bo Hoon , Fong, ChinTo, Orsini, Joseph, Schultz, Matthew J, Gavrilov, Dimitar , Matern, Dietrich , Hall, Patricia L., Tortorelli, Silvia , Orsini, Joseph J. , White, Amy L , Lee, Bo Hoon , Orsini, Joseph J , Matern, Dietrich , Tortorelli, Silvia , Stander, Zinandré , Lynch, Matthew , Coman, David , Bailey, Diana, Oglesbee, Devin

Mayo Clinic

International Journal of Neonatal Screening | April 17, 2026 | Volume: 12 | Issue: 2 | Pages: 25

10.3390/ijns12020025 | PMID 42029543 Get It

COASY-related disorders (CRDs) are a spectrum of autosomal recessive conditions caused by the dysfunction of CoA synthase, an enzyme responsible for the final steps of CoA synthesis. Clinical manifestations of CRDs are highly variable, ranging from perinatal lethal pontocerebellar hypoplasia to childhood-onset neurodegenerative brain iron accumulation, which is often recognized after clinical regression. Recent reports have described a few individuals with CRD who screened positive for carnitine palmitoyltransferase-I deficiency by newborn screening (NBS). However, heterogeneous clinical presentations, conflicting biochemical/molecular sequencing of CPT1A, and a lack of metabolic characterization have led to lengthy, costly diagnostic journeys. To address some of these aspects, this investigation retrospectively evaluated NBS acylcarnitine patterns in five CRD cases using Collaborative Laboratory Integrated Reports (CLIR). A total of 25 metabolites/ratios were identified to deviate significantly from reference ranges and were primarily composed of elevated free carnitine and reduced long-chain acylcarnitine levels. While low acylcarnitine concentrations are often not reported due to a lack of lower reference cutoffs, ratios involving these metabolites relative to short-chain acylcarnitines could aid in identifying CRD cases via NBS. When comparing this pattern to CPT-Ia cases, we confirmed a nearly identical acylcarnitine pattern between these, and thus support the need to consider CRD in cases with NBS results suggestive of CPT-Ia. This study is the first case series to characterize NBS patterns in patients with CRD and highlights the unique opportunity for early detection, particularly in cases that are neonatally asymptomatic and have unremarkable confirmatory biochemical results.
Abstract 1401: A novel statistical framework for surrogate endpoint prediction of survival in neoadjuvant breast cancer trials.
Santos-Parker, Keli S. , Santos-Parker, Jessica R, Esserman, Laura J., DeMichele, Angie, Veer, Laura Van't, Yee, Doug, Reyal, Fabien, Earl, Helena , Cameron, D. , Hall, Peter, Boughey, Judy, Goetz, Matthew, Sonke, Gabe, Martín, Miguel, López-Tarruella, Sara, Sharma, Priyanka, Freiberg, Rachel, Perlmutter, J, Bardia, Aditya, Eklund, Martin, Pusztai, Lajos, Santos‐Parker, Jessica R. , Symmans, W. Fraser , Esserman, Laura J. , Yau, Christina , Yee, Douglas , Reyal, Fabien , Abraham, Jean , Cameron, David, Goetz, Matthew P. , Martín, Miguel , López‐Tarruella, Sara , Sharma, Priyanka , Bardia, Aditya , Pusztai, Lajos

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1401-1401

10.1158/1538-7445.am2026-1401 Get It

Abstract Introduction: Pathological complete response (pCR) is a strong prognostic marker, but survival outcomes comparing treatment to control do not reliably align with treatment-control differences in pCR rates in breast cancer. A novel Bayesian hierarchical framework models treatments within trials, allowing us to predict treatment effects on distant recurrence-free survival (DRFS) from pCR with greater accuracy. Methods: We analyzed 12 neoadjuvant breast cancer trials (6,000 patients, all HR/HER2 subtypes; including I-SPY2). The framework of Burzykowski, Molenberghs & Buyse (2005) is extended to a novel arm-based hierarchical structure providing a distribution of pCR and DRFS treatment effects controlling for subtype (HR/HER2), N and T stage, grade, and calendar year. Three held-out trials (877 patients; 26 regimens; med follow-up &gt;4 years) validate predictions of DRFS treatment benefit from pCR. All data was used to estimate treatment-effect correlation and the surrogate threshold effect (STE). Analyses were repeated for Residual Cancer Burden Index (binary RCB01, continuous RCB). Results: Predicted probability of DRFS benefit closely matched actual DRFS follow-up (mean absolute error 0.06; Pearson r = 0.9). Across all trials, pCR showed moderate surrogacy (ρ = 0.82, R2 = 0.67). A 60% increase in pCR odds achieves ≥95% probability of DRFS benefit (STE = OR of 1.60). RCB outperforms pCR across all metrics, with 92% sensitivity and 93% specificity for detecting DRFS benefit in 26 validation regimens (Table 1). Conclusion: This novel Bayesian meta-analytic framework reveals that pCR, RCB01 and continuous RCB reliably predict survival benefit across heterogeneous trials, with RCB performing the best in an external validation. This provides a statistical foundation for accelerated approval decisions using robust early biomarkers in modern neoadjuvant trial designs by accurately predicting survival at the treatment arm level. Citation Format: Keli S. Santos-Parker, Jessica R. Santos-Parker, W. Fraser Symmans, Laura J. Esserman, Christina Yau, Angie DeMichele, Laura van't Veer, Doug Yee, Fabien Reyal, Helena Earl, Jean Abraham, David Cameron, Peter Hall, Judy Boughey, Matthew Goetz, Gabe Sonke, Miguel Martín, Sara López-Tarruella, Priyanka Sharma, Rachel Freiberg, Jane Perlmutter, Aditya Bardia, Martin Eklund, Rachel Freiberg, Lajos Pusztai. A novel statistical framework for surrogate endpoint prediction of survival in neoadjuvant breast cancer trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1401.
Risk of Multiple Sclerosis Among Persons With Epstein-Barr Virus–Positive Mononucleosis
Hall, Susan A. , Jacobson, Robert M. , Keegan, B. Mark, Fan, Chun , McPhee, Roderick , Buck, Philip O. , Diaz-Decaro, John, Keegan, B. Mark , Keegan, B Mark , Jacobson, Robert M , Sauver, Jennifer L. St. , Diaz‐Decaro, John

Mayo Clinic

Neurology Open Access | April 1, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1212/wn9.0000000000000082 | PMID 42022360 Get It